Gif-sur-Yvettte, France

Johannes Schoemaker


Average Co-Inventor Count = 4.8

ph-index = 3

Forward Citations = 21(Granted Patents)


Location History:

  • Gif sur Yvette, FR (1991)
  • Gif-sur-Yvettte, FR (1994)
  • Gif S/Yvette, FR (1995)

Company Filing History:


Years Active: 1991-1995

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Johannes Schoemaker

Introduction

Johannes Schoemaker is a notable inventor based in Gif-sur-Yvette, France. He has made significant contributions to the field of chemistry, particularly in the development of piperidine derivatives. With a total of 3 patents to his name, Schoemaker's work has implications in therapeutic applications.

Latest Patents

Schoemaker's latest patents include innovative compounds that are piperidine derivatives. One of his patents focuses on a compound which is a piperidine derivative of formula (I), where R represents hydrogen or an unbranched or branched C1-C6 alkyl group. Another patent details a piperidine derivative of general formula (I), which can be used for the treatment and prevention of disorders involving 5-HT receptors. This compound includes various substituents that enhance its therapeutic potential.

Career Highlights

Johannes Schoemaker is associated with Synthelabo, a company known for its research and development in pharmaceuticals. His work at Synthelabo has allowed him to explore and innovate in the field of medicinal chemistry, contributing to advancements in drug development.

Collaborations

Schoemaker has collaborated with notable colleagues such as Samir Jegham and Thomas A Purcell. These collaborations have fostered a productive environment for research and innovation, leading to the successful development of new compounds.

Conclusion

Johannes Schoemaker's contributions to the field of chemistry, particularly through his patents on piperidine derivatives, highlight his role as an influential inventor. His work continues to impact therapeutic applications and showcases the importance of innovation in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…